eumelanin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material may be hygroscopic |
| Solubility class | Soluble in water, DMSO and DMF | Dilution into aqueous buffer can cause precipitation |
| Storage of solid | Minus 20 degrees C, desiccated, dark | Aliquot to limit repeated opening of the vial |
| Storage of solution | Minus 20 to minus 80 degrees C, aliquoted | Avoid repeated freeze-thaw cycles |
| Identity method | Reversed-phase HPLC with mass spectrometry | Retention time and mass are checked together |
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Bate-Smith, E. C. (Sep 1954). "Leuco-Anthocyanins". Biochem. J. 58 (1): 122–125. doi:10.1042/bj0580122. PMC 1269852. PMID 13198862. Pecket, R.C. Constituents of Leaf Extracts ... , New Phytologist 1959 Oct; 58(2) (retrieved 27 sept 2010 http://onlinelibrary.wiley.com/doi/10.1111/j.1469-8137.1959.tb05350.x/pdf ) Stecher, G. and Bonn, G. K., Phytochemical Analysis, Chromatography, Elsevier Science, E. Heftmann (ed), Amsterdam, pp. 1050. ISBN 0-444-51108-3 (2004) (retrieved via google books 9/27/2010)
The ascent led through forests of chestnut, laurels, and heaths, and onto higher, barren volcanic plains such as Llano del Retama, where vegetation diminished and only shrubs and wildlife remained. At Estancia de los Ingleses, a traditional rest point at about 8,000 feet (2,400 m), the group endured a cold, windy night before continuing the climb at 3 a.m. on 22 June 1799. They crossed the Malpays, an area of broken lava and little vegetation, and reached the summit at 8 a.m. At the peak, the party observed the structure of the volcano, measured ground temperatures, and collected air samples. The elliptical crater showed no recent eruptions inside, but the volcano remained active, with recent lava flows and geothermal activity. The summit provided panoramic views of the surrounding islands and the diverse ecological zones descending from the peak, which Humboldt recorded in a sketch. He noted five distinct vegetation zones, from grasses at the summit to cultivated tropical and temperate plants near the coast. The descent took the party back through the varying ecological regions. Humboldt made broader geological observations, considering questions about the structure and origins of volcanoes and the laws governing geological phenomena. The round trip from La Orotava to the summit and back lasted twenty-one hours. The Pizarro’s departure was delayed until 24 or 25 June 1799 due to the presence of an English squadron, allowing Humboldt and Bonpland additional time to explore the island’s surroundings.
Jerden later said that he was told Staley felt animosity toward him dating back to the Dirt sessions due to Jerden repeatedly recommending to Staley that he get sober. Jerden said, "Apparently he got all mad at me [during the Dirt sessions] ... And what's my job as a producer? To produce a record. I'm not getting paid to be Layne's friend". Staley was not the only one who went through heavy drug use; drummer Sean Kinney and bassist Mike Starr were both struggling with alcoholism, while the latter was also addicted to heroin. Jerden got the album's famous guitar tone by blending three different amps – a Bogner Fish preamp for the low end, a Bogner Ecstacy for the mid frequencies, and a Rockman Headphone amp for the high frequencies.
== External links == Jeffries WB (1999-02-17). "Inverse Agonists for Medical Students". Office of Medical Education - Courses - IDC 105 Principles of Pharmacology. Creighton University School of Medicine - Department of Pharmacology. Retrieved 2008-08-12. Inverse Agonists: An Illustrated Tutorial Panesar K, Guzman F. Pharmacology Corner. 2012
Sources: en.wikipedia.org
Use of higher doses of radioiodine reduces the number of cases of treatment failure, with a penalty for higher response to treatment consisting mostly of higher rates of eventual hypothyroidism, which requires hormone treatment for life. There is increased sensitivity to radioiodine therapy in thyroids appearing on ultrasound scans as more uniform (hypoechogenic), due to densely packed large cells, with 81% later becoming hypothyroid, compared to just 37% in those with more normal scan appearances (normoechogenic).
In the United States alone, sales of the Invega franchise (including Sustenna, Trinza, and Hafyera) reached $3.1 billion in 2024, an 8% increase over the previous year. The market is served primarily by Janssen Pharmaceuticals, with generic competition expected to begin after the key U.S. patent expires on January 26, 2031.
==== Muscle ==== Glycogen storage diseases that involve skeletal muscle typically have exercise-induced (dynamic) symptoms, such as premature muscle fatigue, rather than fixed weakness (static) symptoms. Differential diagnoses for glycogen storage diseases that involve fixed muscle weakness, particularly of the proximal muscles, would be an inflammatory myopathy or a limb-girdle muscular dystrophy. For those with exercise intolerance and/or proximal muscle weakness, the endocrinopathies should be considered. The timing of the symptoms of exercise intolerance, such as muscle fatigue and cramping, is important in order to help distinguish it from other metabolic myopathies such as fatty acid metabolism disorders. Problems originating within the circulatory system, rather than the muscle itself, can produce exercise-induced muscle fatigue, pain and cramping that alleviates with rest, resulting from inadequate blood flow (ischemia) to the muscles. Ischemia that often produces symptoms in the leg muscles includes intermittent claudication, popliteal artery entrapment syndrome, and chronic venous insufficiency. Diseases disrupting the neuromuscular junction can cause abnormal muscle fatigue, such as myasthenia gravis, an autoimmune disease. Similar, are Lambert–Eaton myasthenic syndrome (autoimmune) and the congenital myasthenic syndromes (genetic). Diseases can disrupt glycogen metabolism secondary to the primary disease.
Sources: en.wikipedia.org
== Obesity == Obesity affects bone mineral density (BMD) and fracture risk. While increased weight may enhance BMD due to mechanical loading, it can also elevate fracture risk at specific skeletal sites. Studies suggest that obesity impacts bone quality, potentially increasing fragility. Magnesium is essential for bone health, contributing to bone formation and maintenance. Lower magnesium intake has been linked to reduced BMD, while higher intake may help protect against fractures, particularly in postmenopausal women. While obesity may increase BMD, body fat distribution and metabolic factors can negatively affect bone quality, potentially raising fracture risk.
== Summary == Following several years of unsuccessful petitioning through the United Nations and the International Court of Justice for Namibian independence from South Africa, SWAPO formed the PLAN in 1962 with material assistance from the Soviet Union and sympathetic African states such as Tanzania, Ghana, and Algeria. Fighting broke out between PLAN and the South African security forces in August 1966. Between 1975 and 1988, the SADF staged massive conventional raids into Angola and Zambia to eliminate PLAN's forward operating bases. It also deployed specialist counter-insurgency units such as Koevoet and 32 Battalion, trained to carry out external reconnaissance and track guerrilla movements. South African tactics became increasingly aggressive as the conflict progressed. The SADF's incursions produced Angolan casualties and occasionally resulted in severe collateral damage to economic installations regarded as vital to the Angolan economy. Ostensibly to stop these raids, but also to disrupt the growing alliance between the SADF and the National Union for the Total Independence of Angola (UNITA), which the former was arming with captured PLAN equipment, the Soviet Union backed the People's Armed Forces of Liberation of Angola (FAPLA) through a large contingent of military advisers, along with up to four billion dollars' worth of modern defence technology in the 1980s. Beginning in 1984, regular Angolan units under Soviet command were confident enough to confront the SADF. Their positions were also bolstered by thousands of Cuban troops.
multicellular Composed of more than one cell. The term is used especially to describe organisms or tissues consisting of many cells descendant from the same original parent cell which work together in an organized way, but may also describe groups of nominally single-celled organisms such as protists and bacteria which live symbiotically with each other in large colonies. Contrast unicellular.
Sources: en.wikipedia.org
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.
Peptides are commonly isolated as acetate or trifluoroacetate salts, and the counterion contributes to total mass. Two vials with identical peptide content can therefore differ in weight and in measured response. Residual trifluoroacetate is also relevant in cell-based work because it can influence membrane behaviour.
Degradation products are often closely related to the parent molecule, making them hard to resolve with a single method. Counterion variability adds a further source of scatter between laboratories. Because no pharmacopoeial monograph exists for melanotan-2, groups rely on method-specific validation rather than a shared reference standard.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.